Cargando…

Fulvestrant in advanced breast cancer: evidence to date and place in therapy

Breast cancer is a classical hormone-dependent tumour; therefore, endocrine therapy is the mainstay of treatment for hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer. Until recently, classical endocrine agents such as tamoxifen, steroidal and nonsteroidal ar...

Descripción completa

Detalles Bibliográficos
Autor principal:	Boér, Katalin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502950/ https://www.ncbi.nlm.nih.gov/pubmed/28717399 http://dx.doi.org/10.1177/1758834017711097

Ejemplares similares

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
por: Xu, Liang, et al.
Publicado: (2018)

Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
por: Sammons, Sarah, et al.
Publicado: (2018)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
por: Rocca, Andrea, et al.
Publicado: (2018)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Cryoablation In The Management Of Breast Cancer: Evidence To Date
por: Pusceddu, Claudio, et al.
Publicado: (2019)

Galeterone for the treatment of advanced prostate cancer: the evidence to date
por: Bastos, Diogo A, et al.
Publicado: (2016)

Oestradiol measurement during fulvestrant treatment for breast cancer
por: Owen, Laura J., et al.
Publicado: (2019)

Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials
por: Vergote, I, et al.
Publicado: (2004)

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
por: Cameron, D A, et al.
Publicado: (2008)

Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report
por: Yoo, Changhoon, et al.
Publicado: (2011)

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
por: Elias, Anthony D., et al.
Publicado: (2023)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
por: Heo, Mi Hwa, et al.
Publicado: (2019)

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
por: Varella, Leticia, et al.
Publicado: (2023)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

A method to detect fulvestrant interference in estradiol in breast cancer patients
por: Brito, Margarida, et al.
Publicado: (2023)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
por: Sabale, Ugne, et al.
Publicado: (2017)

Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
por: Liu, Jingyu, et al.
Publicado: (2019)

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer
por: Torrisi, Rosalba, et al.
Publicado: (2022)

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023)

ODP563 Breast Cancer With Liver Metastasis Responds Poorly to Fulvestrant-Based Combination Therapy and Chemotherapy
por: Chien, Christine, et al.
Publicado: (2022)

THU548 The Role Of Sirtuin 3 In Endocrine Therapy Resistant Breast Cancer Cells Response To Fulvestrant
por: de Oliveira, Karla Andrade, et al.
Publicado: (2023)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
por: Raybould, Alison L, et al.
Publicado: (2020)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
por: Telford, Claire, et al.
Publicado: (2019)

The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently
por: Lymperatou, Dionysia, et al.
Publicado: (2013)

Stem Cell Therapy for Retinal Degeneration: The Evidence to Date
por: Sharma, Amit, et al.
Publicado: (2021)

Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer
por: Boér, Katalin
Publicado: (2016)

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
por: Fasching, Peter A., et al.
Publicado: (2020)

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
por: Hawle, H., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_q4r0e7lf2titmukcb4pfpkua0a